Recent Investment Analysts’ Ratings Updates for BioMarin Pharmaceutical (BMRN)

Posted by Caroline Horne on Dec 24th, 2025

BioMarin Pharmaceutical (NASDAQ: BMRN) has recently received a number of price target changes and ratings updates:

12/23/2025 – BioMarin Pharmaceutical had its price target raised by analysts at Truist Financial Corporation from $80.00 to $100.00. They now have a “buy” rating on the stock.
12/22/2025 – BioMarin Pharmaceutical had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
12/22/2025 – BioMarin Pharmaceutical had its price target raised by analysts at HC Wainwright from $55.00 to $60.00. They now have a “neutral” rating on the stock.
12/15/2025 – BioMarin Pharmaceutical had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
12/8/2025 – BioMarin Pharmaceutical had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
12/3/2025 – BioMarin Pharmaceutical was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
12/3/2025 – BioMarin Pharmaceutical was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $60.00 price target on the stock, down previously from $82.00.
12/1/2025 – BioMarin Pharmaceutical had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
11/24/2025 – BioMarin Pharmaceutical had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
11/6/2025 – BioMarin Pharmaceutical had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $61.00 price target on the stock, down previously from $73.00.
11/3/2025 – BioMarin Pharmaceutical was given a new $88.00 price target on by analysts at Tudor Pickering.
11/3/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at Sanford C. Bernstein from $95.00 to $88.00. They now have an “outperform” rating on the stock.
11/1/2025 – BioMarin Pharmaceutical was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
10/28/2025 – BioMarin Pharmaceutical had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $66.00 price target on the stock.
10/28/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at Truist Financial Corporation from $90.00 to $80.00. They now have a “buy” rating on the stock.
10/28/2025 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by analysts at Wolfe Research.
10/28/2025 – BioMarin Pharmaceutical had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $94.00 price target on the stock.
10/28/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at Wells Fargo & Company from $90.00 to $70.00. They now have an “overweight” rating on the stock.
10/28/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at Stifel Nicolaus from $91.00 to $73.00. They now have a “buy” rating on the stock.
10/28/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at Barclays PLC from $86.00 to $80.00. They now have an “overweight” rating on the stock.
10/28/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at Morgan Stanley from $104.00 to $98.00. They now have an “overweight” rating on the stock.
10/27/2025 – BioMarin Pharmaceutical had its price target lowered by analysts at HC Wainwright from $60.00 to $55.00. They now have a “neutral” rating on the stock.

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.